Assessment of chemotherapy-induced anemia in children with cancer

• Autorzy: Antonio Ruggiero , Giorgio Attinà , Melina Haber , Paola Coccia , Ilaria Lazzareschi , Riccardo Riccardi
• Języki publikacji: EN

Abstrakty

EN

Anemia is a common cause of co-morbidity in children with cancer. We reviewed a series of 124 children with non-metastatic cancer to assess the relationship between chemotherapy intensity, severe anemia, and frequency of transfusion. In more than 60% of children who received intensive chemotherapy, transfusions were prescribed compared to 38% and 21% of children treated with standard and mild chemotherapy, respectively. In conclusion, our data suggest that the intensity and duration of chemotherapy constitute important factors in determining the onset of anemia.

Słowa kluczowe

EN

Anemia; Chemotherapy-induced anemia; Children; Cancer; Transfusion

• Czasopismo: Open Medicine
• Rocznik: 2008
• Tom: 3
• Numer: 3
• Strony: 341-345

Daty

wydano

2008-09-01

online

2008-07-10

Twórcy

autor

Antonio Ruggiero

• Division of Paediatric Oncology, Catholic University, 00168, Roma, Italy,

autor

Giorgio Attinà

• Division of Paediatric Oncology, Catholic University, 00168, Roma, Italy

autor

Melina Haber

• Division of Paediatric Oncology, Catholic University, 00168, Roma, Italy

autor

Paola Coccia

• Division of Paediatric Oncology, Catholic University, 00168, Roma, Italy

autor

Ilaria Lazzareschi

• Division of Paediatric Oncology, Catholic University, 00168, Roma, Italy

autor

Riccardo Riccardi

• Division of Paediatric Oncology, Catholic University, 00168, Roma, Italy

Bibliografia

• [1] Leitgeb C., Pecherstorfer M., Fritz E., Ludwig H., Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin, Cancer, 1994, 73(10), 2535–42 http://dx.doi.org/10.1002/1097-0142(19940515)73:10<2535::AID-CNCR2820731014>3.0.CO;2-5[Crossref]
• [2] Corazza F., Beguin Y., Bergmann P., Andre M., Ferster A., Devalck C., Fondu P., Buyse M., Sariban E., Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production, Blood, 1998, 92(5),1793–8 [PubMed]
• [3] Lai J.S., Cella D., Kupst M.J., Holm S., Kelly M.E., Bode R.K., Goldman S., Measuring fatigue for children with cancer: development and validation of the pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (pedsFACIT-F), J. Pediatr. Hematol. Oncol., 2007, 29(7), 471–9 http://dx.doi.org/10.1097/MPH.0b013e318095057a[WoS][Crossref]
• [4] Jelkmann W., Developments in the therapeutic use of erythropoiesis stimulating agents, Br. J. Haematol., 2008, 141(3), 287–97 [PubMed]
• [5] Dainiak N., Kulkarni V., Howard D., Kalmanti M., Dewey M.C., Hoffman R., Mechanisms of abnormal erythropoiesis in malignancy, Cancer, 1983, 51(6), 1101–6 http://dx.doi.org/10.1002/1097-0142(19830315)51:6<1101::AID-CNCR2820510622>3.0.CO;2-G[Crossref]
• [6] Ludwig H., Fritz E., Anemia in cancer patients, Semin. Oncol. 1998, 25(3 Suppl 7), 2–6
• [7] Ludwig H., Epoetin in cancer-related anaemia, Nephrol. Dial. Transplant., 1999, 14(S2), 85–92 http://dx.doi.org/10.1093/ndt/14.suppl_2.85[Crossref]
• [8] Mercadante S., Gebbia V., Marrazzo A., Filosto S., Anaemia in cancer: pathophysiology and treatment, Cancer Treat. Rev., 2000, 26(4), 303–11 http://dx.doi.org/10.1053/ctrv.2000.0181[Crossref]
• [9] Shankar A.G., The role of recombinant erythropoietin in childhood cancer, Oncologist,. 2008, 13(2),157–66 http://dx.doi.org/10.1634/theoncologist.2007-0126[Crossref][WoS]
• [10] Means R.T. Jr, Krantz S.B., Progress in understanding the pathogenesis of the anemia of chronic disease, Blood, 1992, 80(7),1639–47
• [11] Groopman J.E., Itri L.M., Chemotherapy-induced anemia in adults: incidence and treatment, J. Natl. Cancer Inst., 1999, 91(19), 1616–34. Erratum in: J. Natl. Cancer Inst., 2000, 92(6), 497 http://dx.doi.org/10.1093/jnci/91.19.1616[Crossref]
• [12] Ruggiero A., Riccardi R., Interventions for anemia in pediatric cancer patients, Med. Pediatr. Oncol., 2002,39(4),451–4 http://dx.doi.org/10.1002/mpo.10184[Crossref]
• [13] Miller C.B., Jones R.J., Piantadosi S., Abeloff M.D., Spivak J.L., Decreased erythropoietin response in patients with the anemia of cancer, N. Engl. J. Med., 1990, 322(24), 1689–92 [Crossref]
• [14] Adamson J.W., Ludwig H., Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer, Oncology, 1999, 56(1), 46–53 http://dx.doi.org/10.1159/000011929[Crossref]
• [15] Schapira L., Antin J.H., Ransil B.J., Antman K.H., Eder J.P., McGarigle C.J., Goldberg M.A., Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy, Blood, 1990, 76(11), 2354–9
• [16] Marc-Berad P., Blay J.K., Schell M., Buclon M., Demaret C., Ray-Coquard I., Risk model predictive of severe anemia requiring RBC transfusion after chemotherapy in pediatric solid tumor patients, J. Clin. Oncol., 2003, 21, 4235–9 http://dx.doi.org/10.1200/JCO.2003.09.121[Crossref]
• [17] Cascinu S., Fedeli A., Luzi Fedeli S., Catalano G., Cisplatin-associated anemia treated with subcutaneous erythropoietin. A pilot study, Br. J. Cancer, 1993, 67, 156–58 [Crossref]

Identyfikatory

DOI

10.2478/s11536-008-0049-3